Conference Coverage
Conference Coverage
Most adult epilepsy-related deaths could be avoided
“The overall mortality is not reducing; people are dying young, and neurologists are really not getting involved.”
Conference Coverage
Telerehabilitation may be effective in MS
Patients with MS may achieve equivalent benefits and increased cost savings with telerehabilitation, compared with outpatient rehabilitation.
Conference Coverage
No benefit of three commonly used medications for MS fatigue
These findings will hopefully encourage doctors to “think twice before prescribing these medications that could be harmful and have no clear...
Latest News
Despite guidelines, controversy remains over corticosteroids in COVID-19
There are conflicting recommendations on the use of corticosteroids in critically ill patients with COVID-19.
Conference Coverage
Nilotinib is safe in moderate and advanced Parkinson’s disease
Although the drug is safe and tolerable, it penetrates the brain poorly and does not change levels of dopamine or its metabolites.
Conference Coverage
Ofatumumab shows high elimination of disease activity in MS
The once-per-month self-injected therapy could offer an alternative to DMTs that require in-office infusion.
Conference Coverage
Natalizumab switch to moderate-efficacy DMT increases disability risk
“Patients transitioning from natalizumab to another high-efficacy therapy have better inflammatory and disability outcomes, compared with those...
Conference Coverage
High levels of air pollution linked to increased MS risk
“Countermeasures that cut air pollution can be important for public health, not only to reduce deaths related to cardiac and pulmonary diseases...
Conference Coverage
Mixed results for aducanumab in two phase 3 trials for Alzheimer’s disease
One of two “identical studies” assessing a novel treatment in development for Alzheimer’s disease reports significant efficacy, while the other...
Conference Coverage
Galcanezumab looks promising for treatment-resistant migraine
The monoclonal antibody reduced the mean number of monthly migraine days in a 3-month open-label extension of the phase 3 CONQUER study.
Conference Coverage
Chronic migraine is associated with changes in the amygdala
Changes in the volume and connectivity of the amygdala are associated with headache frequency and affective states.